Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection

PHASE3CompletedINTERVENTIONAL

Enrollment

255

Participants

Timeline

Start Date

September 7, 2015

Primary Completion Date

November 11, 2016

Study Completion Date

February 4, 2017

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

LDV/SOF

90/400 mg FDC tablet administered orally once daily

DRUG

RBV

Tablets administered orally in a divided daily dose based on weight (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (4)

Cairo

Cairo

Al Mansurah

Shibīn al Kawm